An outbreak of Clostridium difficile infection (CDI) caused by ribotype 027 (B1/NAP1) began in our hospital in November 2014, and produced 141 episodes in the following months. The aim of this study is to describe this outbreak, assess risk factors for recurrence of CDI-027 and to analyze the implementation of a novel treatment strategy. This is a prospective study of all patients with CDI-027, from November 2014 to November 2015. The epidemiological data were collected daily for each patient. We compared clinical characteristics and treatment between patients with and without recurrence of CDI-027. Interestingly, liver cirrhosis was present in 22% of the patients, and most of them received prophylaxis for hepatic encephalopathy with rifaximin. Patients were also taking antimicrobial drugs (93.6%) and proton pump inhibitors (80.1%). Overall, 27 (23.5%) patients had a first recurrence of CDI-027. Liver cirrhosis increased the risk of recurrence (44.4% vs 14.8%). Patients treated with a prolonged oral vancomycin regimen vs the conventional regimen (oral metronidazole or 10 days of vancomycin) had fewer recurrences (8.6 versus 44.7% [p ≤ 0.01]; OR, 0.91; 95% CI, 0.028-0.294) and less attributable mortality (0% versus 7.1%; p = 0.058). We report an outbreak of CDI-027, mainly in patients with liver cirrhosis. Recurrence of CDI-027 was more common in those patients. A novel approach involving high-dose prolonged vancomycin taper as a first-line treatment, together with a bundle of outbreak measures, seemed to reduce the number of cases of CDI-027, recurrences, and attributable mortality. Nevertheless, this approach warrants further investigation.
An outbreak of Clostridium difficile infection ( CDI ) caused by ribotype 027 ( B1/NAP1 ) began in our hospital in November 2014 , and produced 141 episodes in the following months . The aim of this study is to describe this outbreak , assess risk factors for recurrence of CDI-027 and to analyze the implementation of a novel treatment strategy . This is a prospective study of all patients with CDI-027 , from November 2014 to November 2015 . The epidemiological data were collected daily for each patient . We compared clinical characteristics and treatment between patients with and without recurrence of CDI-027 . Interestingly , liver cirrhosis was present in 22 % of the patients , and most of them received prophylaxis for hepatic encephalopathy with rifaximin . Patients were also taking antimicrobial drugs ( 93.6 % ) and proton pump inhibitors ( 80.1 % ) . Overall , 27 ( 23.5 % ) patients had a first recurrence of CDI-027 . Liver cirrhosis increased the risk of recurrence ( 44.4 % vs 14.8 % ) . Patients treated with a prolonged oral vancomycin regimen vs the conventional regimen ( oral metronidazole or 10 days of vancomycin ) had fewer recurrences ( 8.6 versus 44.7 % [ p ≤ 0.01 ] ; OR , 0.91 ; 95 % CI , 0.028 - 0.294 ) and less attributable mortality ( 0 % versus 7.1 % ; p = 0.058 ) . We report an outbreak of CDI-027 , mainly in patients with liver cirrhosis . Recurrence of CDI-027 was more common in those patients . A novel approach involving high - dose prolonged vancomycin taper as a first - line treatment , together with a bundle of outbreak measures , seemed to reduce the number of cases of CDI-027 , recurrences , and attributable mortality . Nevertheless , this approach warrants further investigation .
Which main ribotype of Clostridium difficile is responsible of the recent outbreak?
Which main ribotype of Clostridium difficile is responsible of the recent outbreak ?
Ribotype 027
Ribotype 027